Background-Animal studies suggest that the arginine vasopressin system may play a role in glucose metabolism, but data from humans are limited. Methods and Results-We analyzed plasma copeptin (copeptin), a stable C-terminal fragment of the arginine vasopressin prohormone. Using baseline and longitudinal data from a Swedish population-based sample (nϭ4742; mean age, 58 years; 60% women) and multivariable logistic regression, we examined the association of increasing quartiles of copeptin (lowest quartile as reference) with prevalent diabetes mellitus at baseline, insulin resistance (top quartile of fasting plasma insulin among nondiabetic subjects), and incident diabetes mellitus on long-term follow-up. New-onset diabetes mellitus was ascertained through 3 national and regional registers. All models were adjusted for clinical and anthropometric risk factors, cystatin C, and C-reactive protein.
D
iabetes mellitus is one of the major risk factors for coronary heart disease and congestive heart failure, but the causes of this interaction are not completely understood. One possible link is that hormones implicated in cardiac diseases may play a role in the development of diabetes mellitus. Arginine vasopressin (AVP), also known as antidiuretic hormone, is released from the pituitary gland in conditions of high plasma osmolality, low plasma volume, and low blood pressure. Plasma copeptin, a marker of vasopressin level, is elevated in myocardial infarction 1 and predicts prognosis in patients who develop heart failure after myocardial infarction. 2 Interestingly, recent findings also indicate a cross-sectional association between plasma vasopressin and insulin resistance. 3 
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AVP binds to 3 different receptors (V1aR, V1bR, and V2R). V1aR is widely expressed, 4 whereas V1bR is expressed more specifically in the pituitary gland and pancreas and V2R in the renal collecting ducts. [5] [6] [7] The antidiuretic effect of AVP is mediated through V2R, and pharmacological blockade of V2R has been used to treat hyponatremia 8 and heart failure. 9 The prothrombotic and vasoconstrictor effects of AVP are mediated primarily through V1aR, 10, 11 and AVP agonists have been used to treat bleeding and hypotensive disorders. 12, 13 In addition, AVP action has been linked to liver glycogenolysis (V1aR) and insulin and glucagon secretion (V1bR). 14, 15 Furthermore, AVP stimulates pituitary adrenocorticotropin hormone release (V1bR). 16 This effect has been reported to be resistant to glucocorticoid feedback, suggesting crosstalk between the AVP and hypothalamic-pituitary-adrenalsystems that could be of relevance for diabetes development. 17 Previous studies in humans and animals have suggested a role for the AVP system in glucose homeostasis, insulin resistance, and diabetes mellitus. In patients with poorly controlled diabetes mellitus, plasma AVP is markedly elevated, 18 and in healthy subjects, AVP infusion leads to increased blood glucose levels. 19 Mice lacking V1aR display impaired glucose tolerance, insulin resistance, and elevated AVP levels 20 ; mice that lack V1bR have the opposite phenotype of lower fasting plasma glucose and increased insulin sensitivity. 21 These findings suggest a model in which impaired signaling through V1aR leads to elevated levels of AVP, which in turn stimulates V1bR and contributes to insulin resistance and the development of diabetes mellitus.
There are major concerns regarding the reliability of AVP measurements in plasma because AVP is an unstable molecule both in vivo and ex vivo, is cleared rapidly from plasma, and is largely attached to platelets in the circulation. Copeptin is a cleavage product of the C-terminal part of the AVP precursor that is produced in equimolar amounts with AVP, a process similar to the generation of insulin and C peptide. In contrast to AVP, copeptin is stable, has a long half-life, and is not bound to platelets. Therefore, copeptin is found in considerably higher concentrations in plasma than AVP. 22 Thus, using a validated sandwich assay to measure copeptin in plasma (copeptin), we tested the hypothesis that elevated copeptin is related cross-sectionally to prevalent diabetes mellitus and insulin resistance and longitudinally to increased risk of new-onset diabetes mellitus at the population level.
Methods

Subjects
The Malmö Diet and Cancer study (MDC) is a population-based prospective cohort consisting of 28 449 persons surveyed in 1991 to 1996. 23 From this cohort, 6103 persons were randomly selected to be studied for the epidemiology of carotid artery disease; this sample is referred to as the MDC cardiovascular cohort (MDC-CC). Fasting plasma samples were obtained in 5405 subjects in the MDC-CC. 24 Of those, complete data on covariates, including risk factors for diabetes mellitus, potential confounders, and copeptin, were available in 4742 individuals.
All analyses in plasma and whole blood were performed on overnight fasting samples. Analyses of fasting whole-blood glucose (FBG), plasma lipids, and insulin were carried out at the time of baseline examination at the Department of Clinical Chemistry, Malmö University Hospital, which is attached to a national standardization and quality control system. The limit of detection for insulin was 3 mIU/L, and the intra-assay and interassay coefficients of variation were 5% and 8%, respectively. 25 FBG was measured in whole-blood glucose by a hexokinase-glucose-6-phosphate dehydrogenase method. In fasting plasma samples, we measured copeptin using a commercially available assay in the chemiluminescence/coated-tube format (BRAHMS AG, Hennigsdorf, Germany) as described previously. 26 C-reactive protein was measured by a high-sensitivity assay (Tina-Quant C-reactive protein, Roche Diagnostics, Basel, Switzerland). Cystatin C was measured with a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Dade Behring, Ill).
Blood pressure was measured with a mercury-column sphygmomanometer after 10 minutes of rest in the supine position. Cigarette smoking was elicited by a self-administered questionnaire, with current cigarette smoking defined as any smoking within the past year. Prevalent cardiovascular disease was defined as the occurrence of myocardial infarction or stroke before the baseline examination obtained through national registers as described previously. 24 Family history of diabetes mellitus was obtained by a questionnaire and defined as known diabetes mellitus in at least 1 first-degree relative.
Diabetes mellitus at baseline was defined as self-report of a physician diagnosis or use of diabetes medication or an FBG of Ն6.1 mmol/L (corresponding to fasting plasma glucose concentration of Ն7.0 mmol/L). Subjects who belonged to the top quartile of fasting insulin concentration in the segment of the population without diabetes mellitus were defined as having insulin resistance, as proposed by the European Group for the Study of Insulin Resistance. 27 New-onset diabetes mellitus diagnosed after the baseline examination until December 2005 (mean follow-up time, 12.6 years) was assessed in subjects free of diabetes mellitus at baseline by 3 registers: the Malmö HbA 1c register (MHR), the nationwide Swedish National Diabetes Register (NDR), 28 Subjects who were free of diabetes mellitus at the baseline examination in the MDC-CC, defined by lack of self-reported history of physician-diagnosed diabetes mellitus, use of diabetes medication, and FBG at the baseline examination of Ն6.1 mmol/L, but were registered as diabetes cases any time after their baseline examination in the MDC-CC until December 2005 were classified as having new-onset diabetes mellitus. With these criteria, 174 subjects had new-onset diabetes mellitus during follow-up. Of these, more than half (52%) were identified as new-onset diabetes cases via at least 2 of the 3 registers.
A subset (nϭ887) of the MDC-CC was reinvestigated after a mean of 6.6 years. 30 Of subjects free of diabetes mellitus or without impaired fasting glucose (IFG) at baseline, complete data on covariates, including risk factors for diabetes mellitus, potential confounders, and copeptin, were available in 745 and 620 individuals, respectively. Diabetes development was defined as FBG Ն6.1 mmol/L at the time of follow-up.
The study protocols were approved by the ethics committee of Lund University. All participants provided written informed consent.
Statistical Analyses
SPSS statistical software (version 14.0, SPSS Inc, Chicago, Ill) was used for all analyses except calculation of the C statistics, which was performed with Stata software version 8.0 (Stata Corp, College Station, Tex). Group-wise differences in continuous variables at baseline were tested with the Student t test and reported as meanϮSD if normally distributed and with the Mann-Whitney test and reported as medians and interquartile ranges if not normally distributed. Variables that were not normally distributed were transformed with the natural logarithm when analyzed as continuous variables. Differences in dichotomous variables were tested with 2 tests. The P value for linear trend in FBG and insulin levels over quartiles of copeptin in subjects without diabetes mellitus was assessed with linear regression. We used crude and multivariable-adjusted logistic regression to test whether increasing quartiles of copeptin (quartiles 2 through 4 compared with quartile 1) were related to prevalent diabetes mellitus at baseline in the entire cohort (nϭ4742). In subjects without diabetes mellitus at baseline (nϭ4377), crude regression and multivariable logistic regression were used to test whether increasing quartiles of copeptin were related to insulin resistance and to new-onset diabetes mellitus. In addition, the relationship between increasing quartiles of copeptin and risk of new-onset diabetes mellitus was tested in subjects without IFG at the baseline examination (fasting plasma glucose Ͻ6.1 mmol/L corresponding to an FBG Ͻ5.4 mmol/L; nϭ3702). Finally, multivariable logistic regression was used to test the relationship between increasing quartiles of copeptin and incident diabetes mellitus on the basis of FBG thresholds in the subset of MDC-CC that was reinvestigated. Data from logistic regression analyses are expressed as odds ratios (ORs) and 95% confidence intervals (CIs). A 2-sided value of PϽ0.05 was considered statistically significant.
To assess the sensitivity and specificity of copeptin in predicting new-onset diabetes mellitus in addition to classic diabetes predictors, we compared the area under the receiver-operating characteristic curves using both a personal model (age, gender, body mass index, and family history of diabetes mellitus) and a clinical model (personal model plus systolic blood pressure, triglycerides, high-density lipoprotein, waist circumference, and FBG) as previously proposed 31 with and without copeptin in each of the 2 models. The integrated discrimination improvement was calculated as described previously. 32 We chose logistic regression in our primary analyses rather than Cox regression (time to event) because the diagnosis of diabetes mellitus commonly occurs years after the actual onset of diabetes mellitus. 33 In secondary analyses, we performed Cox regression models with the time of the diabetes event defined as the date of the first HbA 1c value Ն6% in MHR, registration in the Diabetes 2000 register, or registration in NDR. C statistics based on the Cox regressions were calculated as described previously. 34 
Results
Baseline characteristics according to diabetes status are shown in Table 1 . A total of 365 individuals had diabetes mellitus at the baseline examination; 29% had a history of a physician-diagnosis of diabetes mellitus or diabetes treatment; and 71% had an FBG Ն6.1 mmol/L without an accompanying physician diagnosis.
At the baseline examination, copeptin concentrations were higher among individuals with diabetes mellitus compared with subjects without diabetes mellitus (Table 1) . Among nondiabetic subjects at baseline, the Pearson correlations between copeptin and potential confounders, ie, body mass index, insulin, and glucose, were 0.091, 0.12, and 0.10, respectively (PϽ0.001 for all). Increasing quartile of copeptin was associated with an increased odds of diabetes mellitus in a crude model and after multivariable adjustment for all baseline covariates that differed between diabetes patients and subjects without diabetes mellitus (Table 1) except for FBG and fasting plasma insulin concentration (model 1 adjustment) ( Table 2 ). In the segment of the population free of diabetes mellitus, ie, in subjects with a range of glucose values that should not affect copeptin through osmolality, copeptin was positively associated with FBG (the Figure) . Additionally, copeptin was positively associated with plasma concentration of insulin (the Figure) . The odds of insulin resistance increased with increasing copeptin both in crude analysis and after adjustment for model 1 covariates and FBG ( Table 2 ). The association between increasing quartiles of copeptin and the homeostasis model assessment insulin re- sistance index (the product of fasting insulin and FBG) was similar (data not shown). Among participants free of diabetes mellitus at baseline (nϭ4377), 174 subjects developed new-onset diabetes mellitus (Table 3) according to the 3 different registers. MHR captured 106 subjects, whereas the Diabetes 2000 registry and NDR captured 110 and 76 subjects, respectively. Of the 106 diabetes cases diagnosed by MHR, 71% (nϭ75) were also diagnosed in Diabetes 2000 and/or NDR.
When the baseline sample was further restricted to subjects without IFG (nϭ3702), 79 subjects developed new-onset diabetes mellitus during follow-up. Continuous copeptin concentration at baseline was significantly higher in subjects who subsequently developed new-onset diabetes mellitus compared with those who did not, regardless of whether subjects with IFG at baseline were included ( Table 3 ). The likelihood of developing new-onset diabetes mellitus increased with increasing copeptin quartiles in crude logistic regression analysis and after multivariate adjustment (model 1 covariates and fasting insulin, FBG, smoking, diabetes heredity, and low-density lipoprotein) in both subjects free of diabetes mellitus at baseline (P for trend Ͻ0.001, crude; Pϭ0.004, multivariable adjusted) and subjects free of IFG at baseline (PϽ0.001, crude; Pϭ0.001, multivariableadjusted; Table 4 ).
In subjects free of diabetes mellitus at baseline, the area under the receiver-operating characteristic curve increased from 0.694 to 0.710 (Pϭ0.08) when copeptin was added to the personal model and from 0.832 to 0.841 (Pϭ0.007) when copeptin was added to the clinical model of diabetes prediction. In subjects free of IFG at baseline, the area under the receiver-operating characteristic curve increased from 0.663 to 0.713 (Pϭ0.03) and from 0.783 to 0.805 (Pϭ0.04) when copeptin was added to the personal model and clinical model for diabetes prediction, respectively. Integrated discrimination improvement was significantly improved by adding copeptin to the personal model for diabetes prediction in both nondiabetic subjects (Pϭ0.01) and non-IFG subjects (Pϭ0.02) but nonsignificant when added to the clinical model (Pϭ0.35 in nondiabetic individuals, Pϭ0.09 in non-IFG individuals).
To validate the association between copeptin at baseline and the register-based diabetes end point, we assessed the multivariate-adjusted relationship between copeptin and diabetes development on the basis of elevated FBG in a subset of the MDC-CC that was reinvestigated after 6.6 years. Among those free of diabetes mellitus at baseline, 63 subjects had an elevated FBG during follow-up. Increasing quartile of copeptin was associated with new-onset diabetes mellitus using this criterion both in subjects free of diabetes mellitus at baseline (OR, 1.42; 95% CI, 1.04 to 1.94; Pϭ0.03) and in subjects free of IFG at baseline (OR, 1.67; 95% CI, 1.07 to 2.63; Pϭ0.03) after full adjustment (model 1 covariates and fasting insulin, FBG, smoking, diabetes heredity, and low-density lipoprotein), comparable to the findings reported in Table 4 .
Finally, Cox regression models were performed to exclude potential bias related to interindividual differences in follow-up time in the logistic regressions models, and the results were unchanged (Table I in the online-only Data Supplement). C statistics derived from Cox regression models were similar to those from logistic regression models. With the addition of copeptin, the C statistic from Cox regression models increased in subjects without diabetes mellitus at baseline from 0.702 to 0.718 in the personal model and from 0.835 to 0.844 in the clinical model. When analyses were restricted to subjects without IFG at baseline, the C statistic Q indicates quartile. *Analysis of prevalence of diabetes mellitus (nϭ365) in the entire cohort (nϭ4742). †Adjusted for age, sex, high-density lipoprotein, triglycerides, blood pressure, antihypertensive treatment, body mass index, waist, waist-to-hip ratio, cystatin C, C-reactive protein, and previous cardiovascular disease (model 1).
‡Analysis of hyperinsulinemia (highest quartile of fasting plasma insulin concentration among nondiabetic subjects) among nondiabetic subjects (nϭ4377).
§Adjusted for model 1 and FBG.
Figure.
Fasting concentrations of glucose in whole blood and insulin in plasma (the latter transformed using the natural logarithm), expressed as mean with 95% CIs, in nondiabetic subjects belonging to quartiles of increasing copeptin (nϭ4377). P for trend Ͻ0.001 in both analyses. 
Discussion
The key finding of our study is that copeptin predicts the development of diabetes mellitus independently of renal function and a broad range of diabetes risk factors at baseline, including FBG and fasting insulin. The association between baseline copeptin and incident diabetes mellitus was particularly strong in those individuals free of IFG at baseline. As expected, FBG was the strongest risk factor for new-onset diabetes mellitus. Each 1-mmol/L increase in FBG at baseline increased the risk of future diabetes mellitus with an OR of 11.4 (95% CI, 7.4 to 17.5) in the fully adjusted model. Nonetheless, after accounting for FBG and all other available diabetes risk factors, individuals in the top quartile of copeptin had a 2-to 3-fold excess risk of developing diabetes mellitus compared with those in the lowest quartile of copeptin. In subjects without IFG, there was a significant improvement in the area under the receiver-operating characteristic curve when copeptin was added to classic diabetes risk factors, consistent with an improvement in discrimination. Additionally, inclusion of copeptin was associated with a significant integrated discrimination improvement compared with the personal model and a borderline significant integrated discrimination improvement compared with the clinical model. The improvement in the area under the receiveroperating characteristic curve was smaller when the entire sample, including those with IFG, was considered. This finding may result from FBG being a more powerful predictor of diabetes mellitus at FBG levels near the diagnostic limit of 6.1 mmol/L. Markers that are not part of the diagnostic criteria for diabetes mellitus such as copeptin may better signal diabetes susceptibility earlier in the prediabetes state. Novel risk markers as screening tools for future diabetes risk could be particularly useful in individuals with normal FBG, who are likely to be less closely monitored than individuals with IFG. Thus, our findings suggest that copeptin could provide incremental information for the prediction of diabetes mellitus.
Apart from any implications for diabetes prediction, our data support a role for the AVP system in the pathophysiology of diabetes mellitus. Animal studies have shown that mice lacking V1aR display elevated levels of AVP, glucose intolerance, and insulin resistance, whereas mice lacking V1bR have the opposite phenotype of lower FBG and improved insulin sensitivity. 20, 21 From these animal data and our clinical findings, it can be speculated that elevated AVP, as a consequence of AVP resistance at the level of V1aR or elsewhere, could contribute to insulin resistance and diabetes mellitus through stimulation of V1bR. In fact, pharmacological blockade of V2R, a potent stimulus of increased AVP secretion, 35 was associated with a 5% incidence of hyperglycemic events during 30 days of tolvaptan treatment in patients with hyponatremia compared with 1% in control subjects, although the numbers were small (12 of 223 versus 2 of 220). 8 Further studies on the potential metabolic effects of pharmacological manipulation of the AVP system may be warranted.
The diabetes incidence in our study may appear low but was comparable to that in a previous Swedish study. 36 Still, several potential factors could result in a lower-than-expected Abbreviations as in Table 1 . Continuous variables are given as meanϮSD unless otherwise specified.
*Median (interquartile range).
number of new-onset diabetes cases in our study. First, because the participation rate was only 40%, the MDC population is healthier than the background population. 37 Second, the diabetes incidence in the 3 registers is based on people who actively seek health care, leading to a lower incidence than observed in studies that directly screen for diabetes mellitus by measuring FBG. Third, at baseline, the classification of prevalent diabetes mellitus was based solely on FBG Ն6.1 mmol/L in as many as 71% of diabetes patients. Excluding these previously unrecognized diabetes cases from follow-up minimizes the risk that we have incorrectly classified some subjects as incident, instead of prevalent, cases of diabetes mellitus. Finally, because of incomplete register coverage, our study may have missed new-onset cases of diabetes mellitus that were in fact diagnosed within the healthcare system. These factors would be expected to bias our results toward the null. On the other hand, given the strict HbA 1c criterion for new-onset diabetes mellitus in the MHR and the fact that the NDR and the Diabetes 2000 register require a physician diagnosis according to established diagnostic criteria, 28, 29 those cases classified as new onset in our study are unlikely to be misclassified. The validity of the register-based new-onset diabetes diagnosis is further supported by most of the well-known risk factors for diabetes mellitus being markedly elevated at the MDC-CC baseline in these subjects compared with those who did not develop diabetes mellitus according to the 3 registers (Table 3) . Importantly, these differences were equally or more pronounced when the study population was restricted to subjects free of IFG at baseline, excluding the possibility that our findings regarding established diabetes risk factors and copeptin in relation to new-onset diabetes mellitus were driven solely by subjects who had IFG at the MDC-CC baseline examination. The fact that we were able to reproduce the association between copeptin and the register-based diabetes end point using an FBG-based end point in a subset of MDC-CC strongly supports the validity of our findings.
Conclusions
Copeptin predicts diabetes mellitus independently of a broad range of established diabetes risk factors, including fasting levels of glucose and insulin. Our findings suggest a role of the AVP system in the development of diabetes mellitus and may have implications for risk assessment and the development of novel diabetes pharmacotherapy. In addition, our results highlight the possibility that existing therapies that selectively antagonize AVP receptors could have metabolic side effects. *Subjects who developed diabetes mellitus during follow-up (nϭ174) among subjects without diabetes mellitus at baseline (nϭ4377). †Adjusted for age, sex, high-density lipoprotein, triglycerides, blood pressure, antihypertensive treatment, body mass index, waist, waist-to-hip ratio, cystatin C, C-reactive protein, prevalent cardiovascular disease, smoking, family history of diabetes mellitus, low-density lipoprotein, FBG, and fasting insulin.
‡Subjects who developed diabetes mellitus during follow-up (nϭ79) among subjects without IFG at baseline (nϭ3702). 
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